Showing results (371-380 of 453) with videos related to

Sort By:
Pageof 46
Blood Advances|September 6, 2023
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registryJean Lemoine, Emmanuel Bachy, Guillaume Cartron, et al.
Neurology|October 18, 2022
Brain Metabolic Profile in Presymptomatic GRN Carriers Throughout a 5-Year Follow-upDario Saracino, Leila Sellami, Hugo Boniface, et al.
ESMO Open|March 4, 2026
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RETJ Hadoux, J Hernando, K H Wong, et al.
The Journal of Clinical Investigation|May 20, 2014
Targeting CD137 enhances the efficacy of cetuximabHolbrook E Kohrt, A Dimitrios Colevas, Roch Houot, et al.
Nature Cancer|April 3, 2025
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA studyGuillaume Cartron, Roch Houot, Yassine Al Tabaa, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 18, 2025
Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d'Enregistrement et Suivi des patients traités par CAR-T cells) registryAmélie Bouvier, Amandine Durand, Vivien Dupont, et al.
The Lancet. Haematology|September 24, 2020
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA groupSteven Le Gouill, Asma Beldi-Ferchiou, Marion Alcantara, et al.
Journal of Hematology & Oncology|July 3, 2026
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control armGuillaume Cartron, Isabelle Chaillol, Roch Houot, et al.
Blood|December 22, 2021
Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA studyEmmanuel Bachy, Roch Houot, Pierre Feugier, et al.
Blood|September 6, 2024
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphomaKatie Maurer, Isabella N Grabski, Roch Houot, et al.
Pageof 46